Preventing prescription stimulant diversion and misuse through brief intervention: Moderators and secondary outcomes from a randomized controlled trial.
Experimental and Clinical Psychopharmacology · 2026
DOI: 10.1037/pha0000808 ↗At a glance
Randomisierte kontrollierte Studie in Experimental and Clinical Psychopharmacology, 2026. Written by Laura J Holt and 3 co-authors. Institution: Department of Psychology, Trinity College. Major MEDLINE topics: Central Nervous System Stimulants, Prescription Drug Misuse, Attention Deficit Disorder with Hyperactivity, Prescription Drug Diversion. The full text is freely available in PubMed Central. Funded by: NIDA NIH HHS, National Institutes of Health; National Institute on Drug Abuse, National Institutes of Health.
Abstract (original language)
Prescription stimulant diversion (PSD) and misuse (PSM) are prevalent among young adults with stimulant prescriptions and have been associated with conduct problems and poorer attention-deficit/hyperactivity disorder symptom management, functional impairment, and other substance use and misuse. Few evidence-based interventions address PSD and PSM; to date, no research has examined for whom these interventions are most/least effective and potential downstream benefits on psychosocial functioning. In the present study, we examined whether conduct problems in childhood moderated response to an interactive web-based intervention focused on preventing PSD and PSM and whether immediate release prescriptions were associated with more PSD and PSM. We also evaluated the impact of the intervention on functional impairment, binge drinking, other substance use, and accidental injuries. We randomized students from three U.S. universities with current stimulant prescriptions (Mage = 20.42 years, 74% female, 86% White) to the intervention (n = 128) or attention-matched placebo (n = 121) in a single-blind design, with 3- and 6-month follow-ups. Conduct problems and being prescribed an immediate release medication were associated with a greater likelihood of PSD, but not PSM; however, conduct problems were not associated with a differential response to the intervention (any PSD/PSM). Compared to the placebo, the intervention group reported lower attention-deficit/hyperactivity disorder impairment and substance use at the 6-month follow-up; rates of accidental injuries did not differ between the two groups. Findings suggest the intervention had significant but modest effects on psychosocial outcomes. Future targeted interventions for PSD may focus on students with conduct problem histories and/or immediate release prescriptions. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Psychology, Trinity College.
- Department of Psychology, University of Wyoming.
- Department of Psychology, Texas State University.
- Frank H. Netter School of Medicine, Quinnipiac University.
ORCID profiles: Laura J Holt, Alison Looby, Ty S Schepis, Richard Feinn
Funding
- NIDA NIH HHS
- National Institutes of Health; National Institute on Drug Abuse
- National Institutes of Health
Cite
APA
Holt, L. J., Looby, A., Schepis, T. S., & Feinn, R. (2026). Preventing prescription stimulant diversion and misuse through brief intervention: Moderators and secondary outcomes from a randomized controlled trial. Experimental and Clinical Psychopharmacology. https://doi.org/10.1037/pha0000808
Vancouver
Holt LJ, Looby A, Schepis TS, Feinn R. Preventing prescription stimulant diversion and misuse through brief intervention: Moderators and secondary outcomes from a randomized controlled trial. Experimental and Clinical Psychopharmacology. 2026. doi:10.1037/pha0000808
BibTeX
@article{Holt2026,
author = {Holt, Laura J and Looby, Alison and Schepis, Ty S and Feinn, Richard},
title = {Preventing prescription stimulant diversion and misuse through brief intervention: Moderators and secondary outcomes from a randomized controlled trial},
journal = {Experimental and Clinical Psychopharmacology},
year = {2026},
doi = {10.1037/pha0000808}
}
EUVIMED